Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Chapman

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Nature Reviews. Clinical Oncology|July 11, 2012
Thrombosis and cancerAnnie Young, Oliver Chapman, Carole Connor, et al.
Iscience|August 19, 2024
Pursuing multifaceted-disciplinarity to enrich the future of justice in sustainability scienceVishal Sharma, Sarah H Roney, Olanike Olaomo, et al.
Environmental Science & Technology|April 11, 2024
Achieving Decentralized, Electrified, and Decarbonized Ammonia ProductionCarlos A Fernández, Oliver Chapman, Marilyn A Brown, et al.
Journal of Clinical Pathology|March 6, 2010
Does rituximab aggravate pre-existing hypogammaglobulinaemia?Lavanya Diwakar, Sheryl Gorrie, Alex Richter, et al.
Thrombosis and Haemostasis|February 1, 2013
Microsatellite markers as a rapid approach for autozygosity mapping in Hermansky-Pudlak syndrome: identification of the second HPS7 mutation in a patient presenting late in lifeGillian C Lowe, Isabel Sánchez Guiu, Oliver Chapman, et al.
Journal of Thrombosis and Haemostasis : JTH|January 30, 2020
Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)Andrea Marshall, Mark Levine, Catherine Hill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)Annie M Young, Andrea Marshall, Jenny Thirlwall, et al.
Blood|June 4, 2017
Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpuraFerras Alwan, Chiara Vendramin, Karen Vanhoorelbeke, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Nature Reviews. Clinical Oncology|July 11, 2012
Thrombosis and cancerAnnie Young, Oliver Chapman, Carole Connor, et al.
Iscience|August 19, 2024
Pursuing multifaceted-disciplinarity to enrich the future of justice in sustainability scienceVishal Sharma, Sarah H Roney, Olanike Olaomo, et al.
Environmental Science & Technology|April 11, 2024
Achieving Decentralized, Electrified, and Decarbonized Ammonia ProductionCarlos A Fernández, Oliver Chapman, Marilyn A Brown, et al.
Journal of Clinical Pathology|March 6, 2010
Does rituximab aggravate pre-existing hypogammaglobulinaemia?Lavanya Diwakar, Sheryl Gorrie, Alex Richter, et al.
Thrombosis and Haemostasis|February 1, 2013
Microsatellite markers as a rapid approach for autozygosity mapping in Hermansky-Pudlak syndrome: identification of the second HPS7 mutation in a patient presenting late in lifeGillian C Lowe, Isabel Sánchez Guiu, Oliver Chapman, et al.
Journal of Thrombosis and Haemostasis : JTH|January 30, 2020
Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)Andrea Marshall, Mark Levine, Catherine Hill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)Annie M Young, Andrea Marshall, Jenny Thirlwall, et al.
Blood|June 4, 2017
Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpuraFerras Alwan, Chiara Vendramin, Karen Vanhoorelbeke, et al.
Pageof 1